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Policy Forum
During the 1990s, high levels of Plasmodium falciparum(Pf ) resistance to common 
antimalarials were reported from 
malaria-endemic countries, raising 
questions about the efficacy of 
chloroquine (CQ), then the mainstay 
of antimalarial treatment. Drug 
resistance was considered a prime 
contributing factor to increased 
malaria mortality and morbidity across 
Africa [1,2]. The natural successor to 
CQ, sulfadoxine-pyrimethamine (SP), 
had a short therapeutic lifespan [3], 
and the choice of an effective first-line 
regimen emerged as a key issue in Pf 
malaria control. Artemisinin-based 
combination therapy (ACT), adopted 
in southeast Asia since the early 1990s, 
appeared to be the best available 
option [3]. 
Médecins Sans Frontières (Doctors 
Without Borders, or MSF) is a 
humanitarian medical aid organisation, 
dedicated to providing assistance 
to populations who lack access to 
health care. In the 1990s, antimalarial 
resistance was emergent in most 
countries where MSF was operating, 
but scientific evidence of this resistance 
was often lacking, and CQ or SP 
were still recommended by national 
malaria control programmes. Faced 
with a lack of data and the reluctance 
of international technical advisors 
and donors to review treatment 
strategies, MSF initiated in vivo 
studies to document the situation in 
its programme locations. While the 
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enrolled in 43 efficacy studies in 18 
countries of Asia and Africa between 
ÈANDÈÈACCOUNTINGÈFORÈONEÈ
fourth of the overall research output in 
these countries. 
sÈ 4HISÈHASÈPROVIDEDÈEXTENSIVEÈEVIDENCEÈ
on the efficacy of most drug regimens 
currently in use for uncomplicated 
MALARIAÈWHICHÈWASÈOFTENÈUSEDÈFORÈ
treatment policy changes by the 
concerned countries.
sÈ 4HEÈGREATESTÈCONTRIBUTIONÈWASÈ
in conflict-affected countries of 
SUB3AHARANÈ!FRICAÈWHEREÈSTUDIESÈ
represent the vast majority of available 
data and where “traditional” academic 
research institutions were not or barely 
represented.
sÈ 4HEÈVASTÈMAJORITYÈOFÈTHEÈSTUDIESÈWEREÈ
PUBLISHEDÈINÈPEERREVIEWEDÈJOURNALS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which shows that research performed 
in difficult settings can be of a high 
enough standard to ensure publication 
and to be useful in policy change.
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role of non-governmental agencies in 
collecting the necessary evidence to 
stimulate and inform policy change in 
international health.
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primary aim was optimising treatment 
strategies for MSF patients, results 
were often used to formulate national 
policy change. Studies followed 
World Health Organization (WHO) 
recommendations [4,5], were usually 
conducted in insecure or difficult-to-
access sites where data were absent, 
and were generally supported by MSF’s 
epidemiological unit, Epicentre, in 
collaboration with national Ministries 
of Health, WHO, and other partners. 
Here, we describe the output of 
MSF’s work in antimalarial efficacy 
assessment during the last decade, 
and place it within the broader 
context of studies leading to regimen 
change from monotherapies to mostly 
artemisinin-based combinations during 
a critical decade in malaria control. 
We also describe challenges and 
lessons learned whilst carrying out this 
research and discuss its role within 
antimalarial policy change. 
Descriptive Analysis of Efficacy 
Studies
Review methods. We identified all 
malaria in vivo drug efficacy studies 
for which MSF was the main sponsor 
during 1996–2004, whether published 
in peer-reviewed journals or existing 
as unpublished reports in MSF 
operational centres (Brussels, Paris, 
Amsterdam, Barcelona, and Geneva; 
unpublished reports are available upon 
request from epimail@epicentre.msf.
org). Only Pf studies were considered. 
For every study, we compiled country 
and site, year of completion, treatment 
group(s) tested, drug allocation 
method, length of post-enrolment 
follow-up (14 days or less; more than 
14 days, i.e., at least 28-day follow-up), 
and failure rate with 95% confidence 
intervals. A treatment group is defined 
as the regimen tested. Multi-centric 
studies simultaneously evaluating 
several treatment groups within the 
same country were treated as single 
studies.
We calculated the proportion of 
MSF study treatment groups among 
all treatment groups tested against
Pf per country during 1996 to 2004 
by consulting the Global Malaria 
Program database (http://www.who.
int/malaria/resistance.html). We 
reviewed the WHO Global Antimalarial 
Drug Policy Database (http://www.
who.int/malaria/treatmentpolicies.
html) and reference document [6] to 
establish the occurrence and timing 
of changes in treatment policy for 
uncomplicated malaria. We did not 
consider the introduction of CQ and 
SP in combination, as this was not 
a recommended option to replace 
either monotherapy [7]. We compared 
the new drug policy to findings and 
recommendations of the relevant 
MSF malaria studies and calculated 
the proportion of countries where 
recommendations made by MSF were 
concordant with subsequent national 
decisions regarding policy change. 
To calculate the proportion of MSF 
papers among all published papers 
published in peer-reviewed journals, 
we searched PubMed to identify 
antimalarial studies published since 
1996 until up to April 2007, performed 
in the countries in which MSF’s studies 
had taken place, and reporting original 
in vivo efficacy data for treatment of 
uncomplicated Pf malaria in non-
pregnant populations. Keywords were 
“malaria” and country of intervention 
(e.g., “Angola”). 
Study output. Between 1996 and 
2004, MSF performed 43 efficacy 
studies or clinical trials in 18 countries, 
of which eight (17%) were in Asia (five 
countries) and 35 (83%) in Africa 
(13 countries) (Figure 1). Half of 
the studies took place in four African 
countries (21/43, 49%): Angola (n = 
5), the Democratic Republic of the 
Congo (DRC, n = 6), Uganda (n = 5), 
and Sudan (n = 5). 12,145 patients 
were enrolled. Most studies (88%) were 
conducted between 2001 and 2004 and 
had a follow-up of 28 days or more (n
= 34, 79%) with genotypic analysis of 
presumed failures/parasite recurrences 
to distinguish recrudescence from re-
infection (Figure 2). Of studies with 
28-day follow-up, 28/34 (82%) were 
published in peer-reviewed journals, 
and three out of 34 (9%) had been 
submitted to peer-reviewed journals 
at the time of writing; conversely, only 
three out of nine (33%) 14-day studies 
were published (Table 1).
Overall, nine (21%) studies were 
single arm, whereas 34 (79%) were 
comparative. Of the comparative 
studies, 22 (65%) were randomised. 
117 treatment groups were investigated, 
of which 69 (59%) were monotherapies 
(SP, n = 27; CQ, n = 24; amodiaquine 
[AQ], n = 15; mefloquine [MQ], n =
3) and 48 (41%) were combinations. 
Most combinations (90%) were 
artemisinin-based (artesunate [AS]-
SP, n = 14; AS-AQ, n = 12; AS-MQ, n 
doi:10.1371/journal.pmed.0050169.g001
Figure 1. &LOWÈ#HARTÈOFÈ3ITESÈANDÈ4YPEÈOFÈ-3&ÈPfÈ%FFICACYÈ3TUDIESÈn
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= 10, artemether-lumefantrine, n = 5; 
dihydroartemisinin-piperaquine, n = 2); 
the remaining five were quinine-SP (n
= 1) or CQ-SP (n = 4). The number of 
ACT studies increased over time, from 
one in 1998 to 20 (80% of total) in 
2004 (Figure 2). 
Contribution of MSF Studies to the 
Evidence for Policy Change
Within these 18 countries and during 
1996–2004, 455 treatment groups 
were investigated, 112 (25%) by MSF 
(Table 2). The proportion of study 
groups investigated by MSF was higher 
for ACTs (46%) than monotherapies 
(19%), and higher in Africa than in 
Asia, both for monotherapies (23% 
versus 9%) and ACTs (57% versus 
29%). Recommendations made by 
MSF were concordant with subsequent 
national decisions regarding policy 
change in 13/18 (72%) of the 
countries of intervention (Asia: two out 
of five [40%]; Africa: 11/13 [84%]). 
Of the 43 MSF studies, 31 (72%) 
were published in peer-reviewed 
journals. MSF studies accounted for 
23% (31/137) of all articles published 
during this period in the 18 countries 
of intervention (Table 3).
MSF’s largest output was in conflict-
affected countries of sub-Saharan 
Africa, including Angola, Burundi, 
Chad, Liberia, Sierra Leone, and 
southern Sudan, where its studies 
represent the vast majority of available 
data, and where “traditional” academic 
research institutions were not or barely 
represented. Overall, MSF’s study 
output accounted for one quarter of 
antimalarial drug efficacy research 
in 18 countries. Most studies were 
published in peer-reviewed journals. 
Challenges and Lessons Learned
Generalisability of results obtained 
in crisis settings. With the exception 
of Sierra Leone, where a national 
multi-centric study was carried out, 
the MSF studies were not necessarily 
representative of national trends. 
Armed conflict, forced displacement 
in Maheba, Zambia and Kailahun, 
Sierra Leone (potentially leading 
to the introduction of more or less 
resistant strains), and conflict-induced 
nutritional crises (leading to lower 
immuno-competence and thus 
impaired host response) that had 
recently affected many of the study 
populations (Angola; Burundi; DRC; 
Lankien, Mapel, and Nuba, southern 
Sudan; Sierra Leone; Amudat and 
Bundibugyo, Uganda) may have 
resulted in systematic differences in 
local antimalarial efficacy compared 
to other regions of the country. 
Evidence suggests that malnourished 
children have an increased risk of 
treatment failure [8–10]. Organisations 
conducting studies in crisis-affected 
settings need to consider the 
generalisability of their data carefully 
in addition to the more general 
problem of extrapolating findings from 
individual sites to wider populations.
Planning and organisational 
strategy. MSF’s contribution was not 
systematically planned but rather ad 
hoc, driven by its programmes. In 
retrospect, MSF’s approach could 
have been more systematic, and more 
adherent to the standards of evidence-
based medicine, in which randomised 
clinical trials are the primary tool by 
which inefficacious treatments are 
replaced once a more efficacious and 
equally safe alternative is identified. 
The approach shifted over time from 
measuring the efficacy of CQ and 
alternative potential partner drugs to 
combine with AS, to assuming that CQ 
was already inefficacious and focusing 
on head-on comparisons of different 
ACT combinations. MSF’s strategy thus 
wavered between building an evidence 
base to argue against continued CQ 
use, trying to establish the baseline 
resistance of typical partner drugs, and 
a more pragmatic approach of directly 
investigating combinations. 
Logistical and implementation 
challenges. Carrying out field research 
in some of the remote settings proved 
extremely challenging. For example, 
Caala, Angola was under military 
siege and affected by a humanitarian 
emergency during the study period. 
In Bundibugyo, Uganda, security 
constraints due to rebel incursions 
necessitated innovative solutions to 
trace patients not attending follow-up, 
including field visits by clinicians and 
laboratory staff. Shabunda, DRC and 
most Sudanese sites were accessible 
only by plane or on foot. Laboratory 
facilities were usually established 
from scratch, without electricity and 
with the threat of possible sources of 
contamination and degradation of 
slides and blood samples. While most 
study personnel were from the country 
itself, it was necessary to either recruit 
qualified professionals from other areas 
of the country, or re-train local staff 
who had been unemployed for years 
doi:10.1371/journal.pmed.0050169.g002
Figure 2. .UMBERÈOFÈ-3&ÈPfÈ%FFICACYÈ3TUDIESÈANDÈ4REATMENTÈ'ROUPSÈ-ONOTHERAPIESÈANDÈ!#4	È
0ERÈ9EARÈOFÈ#OMPLETIONÈnÈ
#ELLSÈWITHÈ8ÈREPRESENTÈSTUDIESÈOFÈDAYÈFOLLOWUPÈORÈLESSÈEMPTYÈCELLSÈREPRESENTÈSTUDIESÈOFÈDAYÈ
follow-up or more. Mono = monotherapies.
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Table 1. MSF PfÈ%FFICACYÈ3TUDIESÈBYÈ3ITEÈ9EARÈOFÈ#OMPLETIONÈ$RUGÈ4ESTEDÈANDÈ2ESULT
Country Site Year Drug Failure
Rate (%)a
95% Confidence 
Interval (%)
Referenceb
At least 28-day follow-up: 34 studies
Myanmar +ACHIN 1998 #1 79.2 n [16]
SP 80.8 n
MQ 23.0 n
MQ-AS3 20.5 n
Laos Sekong 2000 #1 39.7 n [17]
5GANDA Mbarara 2000 SP 59.3 n [18]
SP-AS1 54.0 n
SP-AS3 22.3 n
South Sudan +AJOÈ+EJI 2001 #1 93.9 n [19]
SP 69.9 n
AQ 25.2 n
Myanmar 2AKHINE 2001 MQ15-AS1 5.9 n [20]
MQ25-AS1 3.6 n
MQ25-AS3unsup 3.9 n
MQ25-AS3sup 0.0 n
India !SSAMÈÈ+ARBIÈ!NGLONG 2001 #1 65.9 n [21]
SP 39.0 n
MQ15 4.4 n
MQ15-AS 10.9 n
India Sonitpur 2001 #1 95.8 n [21]
SP 57.1 n
MQ15 7.8 n
MQ15-AS 1.8 n
Sierra Leone Matru 2001 #1 61.8 n "ACHYÈ#È%PICENTREÈ)NTERNALÈ2EPORTÈ
SP 22.4 n
"ANGLADESHÈ #HITTAGONG 2002 Qui-SP 12.9 n [22]
Liberia (ARPER 2002 #1 84.0 n [23]
SP 69.7 n
Liberia (ARPER 2002 AQ 23.5 n [24]
Zambia Maheba 2002 SP-ASsup 16.4 n [25]
SP-ASunsup 36.6 n
5GANDAÈ "UNDIBUGYO 2002 SP 37.0 n [26]
AQ 20.6 n
#130 22.8 n
#HADÈ "ONGOR 2002 #1 23.7 n [27]
SP 16.3 n
AQ 6.4 n
5GANDA Amudat 2003 #130 52.8 n 'RANDESSOÈ&È%PICENTREÈ)NTERNALÈ2EPORTÈ
AQ-AS 14.3 n
SP-AS 7.9 n
"ANGLADESH #HITTAGONG 2003 #130 37.6 n [28]
MQ-AS 0.9 n
A-L 2.9 n
South Sudan .UBA 2003 SP-AS 8.8 n [29]
AQ-AS 7.3 n
Sierra Leone Freetownc 2003 #1 67.8 n [30]
SP 28.0 n
AQ 7.4 n
Sierra Leone +ABALA 2003 #1 39.5 n [30]
SP 23.2 n
AQ 18.2 n
Sierra Leone +AILAHUN 2003 #1 78.8 n [30]
SP 46.1 n
AQ 29.8 n
Sierra Leone Makeni 2003 #1 70.0 n [30]
SP 24.0 n
AQ 5.4 n
Sierra Leone Matru 2003 AQ 13.0 n [30]
.ORTHÈ3UDANÈ Malakal 2003 SP-AS 0.9 n [31]
AQ-AS 1.0 n
Angola #AALA 2003 #1 83.5 n [32]
AQ 17.3 n
SP 25.3 n
Angola +UITO 2003 AQ 21.6 n [32]
SP 38.8 n
AQ-AS 1.2 n
SP-AS 1.2 n
PLoS Medicine  |  www.plosmedicine.org 1195 August 2008  |  Volume 5  |  Issue 8  |  e169
because of health system collapse. The 
vast majority had no prior experience 
in research. Research procedures had 
to be adapted to programmes hitherto 
dedicated solely to emergency health 
care provision. The greatest evidence 
gaps may well be in remote locations 
featuring the most difficult research 
conditions. Organisations must be 
prepared to be flexible, innovative, 
and resourceful. Investment in basic 
infrastructure, training, and human 
resources is essential.
Follow-up and rescue treatment were 
also problematic. The WHO assessment 
Table 1. #ONTINUED
Country Site Year Drug Failure
Rate (%)a
95% Confidence 
Interval (%)
Referenceb
At least 28-day follow-up: 34 studies
South Sudan Mapel 2003 #1 82.7 n "ACHYÈETÈALÈ%PICENTREÈ)NTERNALÈ2EPORTÈ
SP 15.7 n
#HADÈ +OUMRA 2003 #1 32.9 n [27]
SP 4.3 n
AQ 2.2 n
#AMBODIA !NGLONGÈ6ENGÈÈ+VAV 2003 0IPERAQ$(! 2.5 n [33]
MQ-AS 2.5 n
Guinea $ABOLA 2004 SP-AS 1.0 n [34]
AQ-AS 1.0 n
$2#È +ABALO 2004 SP 22.9 n "ONNETÈETÈALÈSUBMITTED
SP-AS 0.0 n
AQ-AS 0.0 n
$2#È Shabunda 2004 SP-AS 19.7 n [35]
AQ-AS 6.8 n
#ONGOÈ +INDAMBA 2004 AQ-AS 1.5 n [36]
SP-AS 9.9 n
A-L 0.0 n
5GANDAÈ Mbarara 2004 A-Lsup 2.3 n [37]
A-Lunsup 2.0 n
Angola #AALA 2004 AQ-AS 0.0 n [38]
A-L 0.0 n
Sierra Leone +AILAHUN 2004 AQ-AS 15.5 n [39]
Mali +OUMANTOU 2004 #1 90.5 n [40]
SP 7.0 n
$2#È "OENDE 2004 SP 43.4 n "ONNETÈETÈALÈSUBMITTED
AQ 25.8 n
SP-AS 32.8 n
AQ-AS 19.0 n
$2#È +ILWA 2004 SP-AS 9.8 n "ONNETÈETÈALÈSUBMITTED
AQ-AS 18.2 n
Myanmar 2AKHINE 2004 0IPERAQ$(! 0.6 n [41]
MQ-AS 0.0 n
14-day follow-up: 9 studies
Angolad -BANZAÈ#ONGO 1997 #1 57.2 n -3&È)NTERNALÈ2EPORTÈ
5GANDA Mbarara 1998 #1 81.1 n [42]
SP 25.0 n
"URUNDI +AYANZA 2001 #1 100.0 n ,EGROSÈ$È$ANTOINEÈ&È%PICENTREÈ2EPORTÈ
SP 74.8 n
#130 56.9 n
"URUNDI +ARUZI 2001 #1 97.8 n ,EGROSÈ$È$ANTOINEÈ&È%PICENTREÈ2EPORTÈ
SP 89.7 n
$2#È Pweto 2001 SP 51.0 n -3&È)NTERNALÈ2EPORTÈ
$2# Multi-centric 2001 #1 45.4 n [43]
SP 7.5 n
South Sudan Lankien 2001 #1 11.5 n [44]
SP 0.0 n
AQ 5.9 n
.IGERIAÈ "AYELSA 2001 #1 70.5 n (ARDWICKÈETÈALÈ-3&È)NTERNALÈ2EPORTÈ
.IGERIAÈ "AYELSA 2002 AQ 8.6 n -3&È)NTERNALÈ2EPORTÈ
Angola Malange 2002 #1 79.7 n 0RINSEBERGÈ4È"ROEDERÈ2È-3&È)NTERNALÈ2EPORTÈ
2002SP 8.6 n
a4HESEÈAREÈUSUALLYÈDAYÈ0#2ÈCORRECTEDÈFAILUREÈRATESÈEXCEPTÈINÈÈSTUDIESÈ;=ÈWHEREÈFAILUREÈRATESÈAREÈGIVENÈATÈDAYÈÈORÈÈ
b5NPUBLISHEDÈREPORTSÈAREÈAVAILABLEÈUPONÈREQUESTÈFROMÈEPIMAIL EPICENTREMSFORG
c3TUDYÈDONEÈBYÈ#ONCERNÈ7ORLDWIDE3IERRAÈ,EONEÈ-INISTRYÈOFÈ(EALTH7(/ÈWITHÈ-3&n%PICENTREÈSUPERVISION
d)NÈTHISÈSTUDYÈTHEÈFOLLOWUPÈWASÈÈDAYS
!,ÈARTEMETHERLUMEFANTRINEÈ!31ÈARTESUNATEÈONEÈDAYÈ!33. artesunate three days; ASsupÈARTESUNATEÈSUPERVISEDÈ!3unsupÈARTESUNATEÈUNSUPERVISEDÈ-115ÈMEFLOQUINEÈÈMGKGÈ-125È
MEFLOQUINEÈÈMGKGÈ0IPERAQ$(!ÈPIPERAQUINEDIHYDROARTEMISININÈ1UIÈQUININE
doi:10.1371/journal.pmed.0050169.t001
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protocol required investigators to 
withhold rescue treatment in case of 
asymptomatic parasite recurrence, 
which carries a high risk of avoidable 
morbidity [11]. Follow-up visits 
took place at one-week intervals, 
during which patients with known 
parasitaemia would remain without 
rescue treatment. On two occasions 
(two children treated respectively with 
AQ and CQ who were parasitaemic 
during follow-up and who did not 
come back for further visits), we believe 
this contributed to avoidable deaths 
from severe malaria. As a response, 
we instituted frequent home visits by 
field workers to detect any symptom 
progression.
Partly due to concerns about security-
related interruptions to enrolment, a 
proportion of studies in the first half 
of the period were single arm or used 
sequential allocation procedures. 
Unplanned decisions to stop enrolment 
due to very high treatment failure 
were occasionally taken, thus exposing 
investigators to the criticism of having 
contravened the protocol; later, 
randomisation was introduced as the 
standard, along with systematic early 
stopping rules. 
Quality versus timeliness. Efforts 
were made to improve the quality of 
the studies, including establishment 
of routine laboratory quality control 
procedures (internal controls 
and review of slides by reference 
laboratories) and standard protocols 
and operating procedures for clinical 
and laboratory work. From 2003, follow-
up was systematically extended to 28 
days, and PCR genotyping analyses were 
always done to adjust failure rates for 
re-infections. This is broadly considered 
an appropriate method for assessing 
drug efficacy and therefore yielded 
realistic estimates for each site [12].
However, these analyses required 
the involvement of partner institutions 
(usually academic laboratories in 
Europe). Due to the heavy workload 
of these laboratories, PCR genotyping 
sometimes yielded considerable delays 
in releasing final results. In situations 
where treatment failure was severe, this 
raised an ethical dilemma of balancing 
the release of final results with the 
need for action. A common approach 
was to release preliminary, unadjusted 
failure rates based on 14-day follow-
up, especially when these already 
warranted an urgent change of the 
current first-line therapy. This however 
often led to confusion, especially when 
subsequent 28-day results overturned 
the initial impression that other cheap 
non-ACT regimens were still efficacious 
(particularly SP, for which failures 
tend to occur late). Furthermore, MSF 
field officers mediating between study 
investigators and local stakeholders did 
not always have the technical expertise 
to discuss genotyping adjustment. With 
more complex methods, the extra 
time involved in ensuring that data 
are accurate must be weighed against 
the urgency of action in each setting. 
However, our experience shows that in 
order to avoid confusion it is preferable 
to await final results, as long as the 
delay is acceptable (to be determined 
on a case-by-case basis). 
Ethical Issues
These studies presented ethical 
dilemmas common to research in
crisis-affected populations [13]. Local
Table 2. .UMBERÈOFÈ3TUDIESÈ0ERFORMEDÈBYÈ-3&n%PICENTREÈAMONGÈ4OTALÈ3TUDIESÈBYÈ#OUNTRYÈANDÈ$RUGÈ-ONOTHERAPYÈ!#4	ÈANDÈ
#ONCORDANCEÈBETWEENÈ-3&È2ECOMMENDATIONSÈANDÈ.EWÈ0OLICYÈ3UBSEQUENTLYÈ!DOPTEDÈBYÈTHEÈ#OUNTRY
Country MSF–Epicentre Studies/Total Studies Year(s) of 
Study
ACT(s)
Recommended by 
MSF
Year of 
Change
New Policy Concordance
between MSF 
Recommendations
and New Policy
Monotherapies ACT Total
n/N % n/N % n/N %
Asia
"ANGLADESH 0/4 0 2/2 100 2/6 33 2003 !3-1È!, 2004 A-L Yes
#AMBODIA 0/0 .! 2/17 12 2/17 12 2003 .ONE 2000 AS-MQ .O
India 6/40 15 2/2 100 8/42 19 2001 AS-MQ 2004 30È!330 .O
Laos 1/9 11 0/4 0 1/13 8 2000 .ONE 2001 A-L .O
Myanmar 3/54 5 7/19 41 10/73 14 Èn AS-MQ 2002 !3-1È!, Yes
Total: Asia 10/107 9 13/44 29 23/151 15
Africa
Angola 8/16 50 4/4 100 12/20 60 Èn !3!1È!, 2004 A-L Yes
"URUNDI 4/8 50 0/4 0 4/12 33 2001 !3!1È!, 2003 AS-AQ Yes
#ONGO 0/5 0 3/3 100 3/8 37 2004 !,È!3!1 .OÈCHANGE .O
$2# 6/19 31 8/14 57 14/33 42 n A-L 2004 AS-AQ .O
Guinea 0/8 0 2/2 100 2/10 20 2004 !330È!3!1 2004 AS-AQ Yes
Mali 2/22 9 0/0 .! 2/22 9 2004 !330È!3!1È!, 2004 A-L Yes
.IGERIA 2/20 10 0/0 .! 2/20 10 n !#4ÈNOÈPRECISION 2004 A-L Yes
Liberia 3/3 100 0/0 .! 3/3 100 2002 AS-AQ 2004 AS-AQ Yes
Sierra Leone 15/17 88 1/1 100 16/18 89 nn AS-AQ 2004 AS-AQ Yes
Sudan 8/40 20 4/10 40 12/50 24 n !330È!, 2004 !3!1È!330 Yes
#HAD 6/7 86 0/0 .! 6/7 86 n AS-AQ 2004 AS-AQ Yes
5GANDA 5/48 10 6/6 100 11/54 20 È
nnn
!3!1È!330È!,È 2004 A-L Yes
Zambia 0/39 0 2/8 25 2/47 4 2002 A-L 2002 A-L Yes
Total: Africa 59/252 23 30/52 57 89/304 29
Total: All 
#OUNTRIES
69/359 19 43/96 46 112/455 25
!,ÈARTEMETHERLUMEFANTRINEÈ.!ÈNOTÈAPPLICABLE
doi:10.1371/journal.pmed.0050169.t002
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clinicians had strong anecdotal 
evidence of poor drug efficacy, but 
lack of scientific evidence hindered 
advocacy to review treatment 
policies. Communities were particularly 
vulnerable to the effects of antimalarial
drug resistance since they had poor 
access to health care, no recourse to 
efficacious second-line treatments, and 
limited civil rights and governance 
structures within which to voice their 
patient perspective. Furthermore, 
patients’ or caregivers’ ability to decide 
whether to participate in the study was 
severely constrained: the study venue 
was often their sole health care option, 
and their familiarity with biomedical 
concepts may have been insufficient 
to properly consider the risks and 
benefits of participation. Adhering to 
the strict follow-up schedule was also 
challenging, potentially entailing days 
of missed work.
In many countries there was no 
institutional review board (IRB), and 
protocols were approved by Ministry 
of Health directorates for research, 
as well as local health authorities. We 
considered that even in the absence of 
formal IRB review, generating evidence 
on antimalarial efficacy was essential 
to stimulate policy change. The 
assessment protocol was standardised 
and recommended by WHO; regimens 
were non-experimental; and patients’ 
risk of untoward outcomes was lower 
than in routine care due to the 
systematic follow-up and availability 
of second-line regimens in case of 
treatment failure. These considerations 
persuaded us that the harm–benefit 
ratio was favourable. This experience 
suggests that ethical risks of conducting 
research should always be weighed 
against the consequences of inaction. 
Measures to minimise risk include 
standardising protocols, ensuring 
locally appropriate, understandable 
consent procedures, developing 
alternative structures for ethics review, 
and involving the community.
Future Research Challenges
Recently, several players have 
become involved in antimalarial 
efficacy assessment, and there are 
global initiatives to co-ordinate studies 
[14]. Today’s challenges are different: 
(1) to detect resistance to ACTs as early 
as possible, best done by combining 
molecular and in vivo studies, and 
defining strategic surveillance sites 
where resistance is more likely to 
arise de novo or be introduced 
from other regions; and (2) to 
demonstrate that new regimens (e.g., 
dihydroartemisinin-piperaquine) are 
at least as efficacious as current first-
line ACTs and carry additional benefits 
in terms of safety, cost, or feasibility: 
this would require non-inferiority 
rather than comparative trial designs 
[15].
Conclusions
Our analysis shows that research 
can be performed in difficult settings 
to a high enough standard to ensure 
publication and to be useful in policy 
change.
MSF’s work shows that non-
governmental organisations (NGOs) 
can provide extensive evidence on the 
efficacy of most antimalarial regimens. 
This evidence probably affected 
malaria treatment policy decisions, 
as suggested by the high number of 
countries where recommendations 
and decisions were the same. However, 
this conclusion has to be drawn with 
caution: factors leading to policy 
change are many and difficult to 
measure, as are reasons for adopting 
one regimen over another.
As part of their mandate, medical 
NGOs should be prepared to fill gaps 
in evidence, including evaluating 
current tools to control tropical 
diseases in hard-to-reach populations, 
and demonstrating the effectiveness of 
alternatives. Dissemination of findings 
in peer-reviewed journals is crucial to 
bolster the validity of such research 
and inform international policy and 
advocacy. While operational research 
can successfully be undertaken by 
NGOs, national malaria control 
programmes, WHO, and other 
major international disease control 
partnerships hold the primary 
responsibility for initiating such studies. 
Had such institutions stimulated a 
systematic process of monitoring 
antimalarial efficacy from the onset 
of reports of drug resistance, change 
might have occurred earlier. Finally, 
it is important that complacency does 
not set in. Artemisinin resistance 
may well arise, and countries, 
international bodies, and NGOs need 
to prospectively monitor the situation 
to avoid history repeating itself. 
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